Sind Östrogene Karzinogene?
Tóm tắt
Từ khóa
Tài liệu tham khảo
ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group (2002) Anastrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 355: 2131–2139
Chen Y, Liu X, Pisha E et al. (2000) A metabolite of equine estrogens, 4 hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 13: 342–350
Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in human breast cancer. Cancer Res 57: 4987–4991
Colditz GA (1998) Relationship between estrogen levels, use of hormone replacement therapy and breast cancer. J Natl Cancer Inst 90: 814–823
Collaborative group on hormonal factors in breast cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047–1059
Emons G, Hoppen HO, Ball P, Knuppen R (1980) 4-Hydroxyestrone, isolation and identification in human urine. Steroids 36: 73–79
Emons G, Mente C, Knuppen R, Ball P (1981) Radioimmunoassay of 4-hydroxyestrone in human urine. Acta Endocrinol (Copenh) 97: 251–257
Emons G, Ball P, Knuppen R (1983) Radioimmunoassays of catechol estrogens. In: Merriam GR, Lipsett MB (eds) Catecholestrogens. Raven, New York, pp 71–83
Emons G, Merriam GR, Pfeiffer D, Loriaux DL, Ball P, Knuppen R (1987) Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. J Steroid Biochem 28: 499–504
Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W (2000) Hormonal interactions in endometrial cancer. Endocr Related Cancer 7: 227–242
Fotsis T, Zhang Y, Pepper M, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368: 237–239
Goodman MT, McDuffle K, Kolonel LN et al. (2001) Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 10: 209–216
Hiraku Y, Yamashita N, Nishiguchi M, Kawanishi (2001) Catecholestrogens induce oxidative DNA damage and estradiol enhances cell proliferation. Int J Cancer 92: 333–337
International Agency for Research on Cancer (1987) Monographs on the evaluation of carcinogenic risks to humans. IARC, Lyon, Frankreich, Suppl 7: 280–285
International Agency for Research on Cancer (1999) Monographs on the evaluation of carcinogenic risks to humans: hormonal contraception and postmenopausal hormone therapy. IARC, Lyon, Frankreich, 72: 474–530
Jefcoate CR, Liehr JG, Santen RJ et al. (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J National Cancer Inst Monogr 27: 95–112
Kuhl H (2002) Sind Estrogene Karzinogene? J Menopause 2: 19–28
Lacey JV, Mink PJ, LubinJH et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288: 334–341
Liehr JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21: 40–54
Liehr JG (2001) Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanisms of uterine and mammary cancer development. Human Reproduction Update 7: 273–281
Mottram DS, Wedzicha BL, Dodson AT (2002) Acrylamide is formed in the Maillard reaction. Nature 419: 448–449
National Toxicology Program, National Institute of Environmental Health Sciences (2000) Report on carcinogens. http://www.niehs.nih.gov/news/rocrslt.htm
Reid SE, Murthy MS, Kaufman M, Scanlon EF (1996) Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 83: 1037–1041
Riman T, Dickman PW, Nilsson S et al. (2002) Hormone replacement therapy and risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94: 497–504
Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285: 1460–1465
Russo J, Hu YF, Yang X, Russo JH (2000) Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Mongr 27: 17–37
Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, Ao X, Russo IH (2002) 17Beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 80: 149–162
Santen RJ (2002) To block estrogen's synthesis or action: that is the question J Clin Endocrinol Metab 87: 3007–3012
Stadler RH, Blank I, Varga N et al. (2002) Acrylamide from Maillard reaction products. Nature 419: 449–450
Thompson PA, Ambrosone C (2000) Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 27: 125–134
Todorovic R, Devanesan P, Higginbotham S, Zhao J, Gross MR, Rogan EG, Cavalieri EL (2001) Analysis of potential biomarkers of estrogen-initiated cancer in the urine of Syrian golden hamsters treated with 4-hydroxyestradiol. Carcinogenesis 22: 905–911
Tsutsui T, Barrett JC (1997) Neoplastic transformation of cultured mammalian cells by estrogens and estrogenlike chemicals. Environ Health Perspect 105 (Suppl 3): 619–624
Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomised controlled trial. JAMA 288: 321–333
Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27: 67–73
Zhu BT, Conney AH (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58: 2269–2277